Holen Sie sich die Stockscreener-App
44.97
0.67%
0.2985
Schlusskurs vom Vortag:
$44.67
Offen:
$44.78
24-Stunden-Volumen:
707.32K
Relative Volume:
0.22
Marktkapitalisierung:
$107.39B
Einnahmen:
$49.41B
Nettoeinkommen (Verlust:
$5.59B
KGV:
18.83
EPS:
2.3875
Netto-Cashflow:
$8.32B
1W Leistung:
+4.95%
1M Leistung:
-4.58%
6M Leistung:
-9.39%
1J Leistung:
-14.99%
1-Tages-Spanne:
$44.55
$44.98
1-Wochen-Bereich:
$42.67
$44.98
52-Wochen-Spanne:
$42.33
$53.03
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
44.94 | 106.76B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,041.33 | 908.57B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.47 | 552.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
214.48 | 375.09B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
188.89 | 290.72B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
151.39 | 287.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2026-01-06 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-12-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Sanofi stock (FR0000120578): Pipeline updates keep investors watching - AD HOC NEWS
Sanofi stock (FR0000120578): trial data and EU approval updates - AD HOC NEWS
1 Dirt Cheap Growth Stock to Buy Right Now - The Motley Fool
Sanofi stock (FR0000120578): Dupixent data and AI investment keep focus on growth - AD HOC NEWS
Sanofi stock (FR0000120578): FDA, dividend and Dupixent keep investors focused - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Q1 figures, GLP-1 hopes and focus on pipeline value - AD HOC NEWS
SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Sanofi S.A. stock (FR0000120578): Q1 2026 results reviewed - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Global pharma leader's business and market position - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Recent earnings and pipeline updates - AD HOC NEWS
Sanofi (NASDAQ:SNY) Emerges as a Decent Value Pick with Strong Fundamentals - ChartMill
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 - ChartMill
European ADRs Open The Week Lower In US Trading - Finimize
Communiqué de presse : Assemblée Générale Annuelle du 29 avril 2026 - GlobeNewswire Inc.
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat - Sahm
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision - Sahm
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises - Investing.com
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises By Investing.com - Investing.com Canada
Sanofi S.A. stock (FR0000127771): Is its biopharma pivot strong enough to unlock new upside? - AD HOC NEWS
Sanofi ADS (SNY) In-Depth Look | Sanofi ADS posts 4.6% EPS beat on pharma revenueADR - Newser
Sanofi S.A. stock (FR0000127771): Is its immunology pipeline strong enough to unlock new upside? - AD HOC NEWS
SNY Earnings History & Surprises | EPS & Revenue Results | SANOFI-ADR (NASDAQ:SNY) - ChartMill
SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Morgan Stanley lowers Sanofi stock price target on FX update - Investing.com UK
Morgan Stanley lowers Sanofi stock price target on FX update By Investing.com - Investing.com Canada
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
AstraZeneca Strengthens Position In COPD Race With Successful Trials - Sahm
Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case - ChartMill
Sanofi S.A. stock faces pressure amid dividend payout and sector headwinds on Euronext Paris - AD HOC NEWS
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):